MoonLake Stockholders with Large Losses are Encouraged to Contact Robbins LLP for Information About the Class Action Against MLTX

Core Viewpoint - MoonLake Immunotherapeutics, a Swiss clinical-stage biotechnology company, is facing a class action lawsuit for allegedly misleading investors about the efficacy of its drug candidate SLK, which is aimed at treating inflammatory diseases driven by interleukin-17 (IL-17) [1][3]. Company Overview - MoonLake is focused on developing treatments for inflammatory diseases, particularly in dermatology and rheumatology, utilizing a unique Nanobody structure [1]. Legal Allegations - The lawsuit claims that during the class period, MoonLake failed to disclose critical information regarding the efficacy of SLK compared to BIMZELX, an FDA-approved drug. Key points include: - Both SLK and BIMZELX target the same inflammatory cytokines IL-17A and IL-17F [3]. - The distinct Nanobody structure of SLK does not provide a clinical benefit over the traditional monoclonal antibody structure of BIMZELX [3]. - Claims of increased tissue penetration by SLK do not translate to improved clinical efficacy [3]. - The company lacked a reasonable basis for its positive statements regarding SLK's superiority [3]. Stock Performance Impact - Following the announcement of disappointing week-16 results from the Phase 3 VELA program on September 28, 2025, MoonLake's stock price plummeted by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [4]. Class Action Participation - Shareholders may be eligible to participate in the class action against MoonLake. Those wishing to serve as lead plaintiffs must submit their papers by December 15, 2025 [5]. Legal Representation - Robbins LLP is leading the class action, specializing in shareholder rights litigation and has been active in helping shareholders recover losses and improve corporate governance since 2002 [6].